Cisplatin: Chemotherapeutic Compound and DNA Crosslinking Agent for Cancer Research

Executive Summary: Cisplatin (CAS 15663-27-1), supplied by APExBIO, is a platinum-based chemotherapeutic compound with a molecular weight of 300.05 and formula Cl2H6N2Pt. It induces apoptosis by forming DNA crosslinks, activating p53, and triggering caspase-3 and -9 cascades (APExBIO). Cisplatin also elevates reactive oxygen species (ROS), driving ERK-dependent apoptotic signaling (Zhang et al., 2025). It is a gold-standard agent in cancer research, especially for studying chemotherapy resistance and DNA damage response. The compound is insoluble in water and ethanol but dissolves in DMF at ≥12.5 mg/mL and must be freshly prepared for experimental reproducibility.

Biological Rationale

Cisplatin, also known as CDDP, is a widely used DNA crosslinking agent for cancer research. Its primary action is to form intra- and inter-strand crosslinks at guanine bases in DNA. This blocks both DNA replication and transcription. Disrupted DNA integrity activates cellular checkpoints and repair systems. Persistent lesions lead to the activation of apoptosis, particularly via p53-mediated and caspase-dependent pathways (Cisplatin: DNA Crosslinking Agent and Apoptosis Inducer in Cancer Research). The compound’s cytotoxicity underpins its use in model systems to dissect mechanisms of resistance, apoptosis, and tumor suppression.

Mechanism of Action of Cisplatin

Cisplatin exerts cytotoxic effects by binding DNA and forming covalent crosslinks, predominantly at N7 positions of guanine bases. This interaction causes replication fork stalling and transcriptional arrest. The DNA damage is sensed by p53, which orchestrates cell cycle arrest or triggers apoptosis. Downstream, caspase-3 and caspase-9 are activated, resulting in programmed cell death (Zhang et al., 2025). Cisplatin also induces oxidative stress by elevating ROS levels, promoting lipid peroxidation, and engaging ERK-dependent apoptotic signaling pathways. Notably, the compound is inactivated by reaction with thiol-containing solvents (e.g., DMSO), which underscores the need for precise handling (APExBIO).

Evidence & Benchmarks

• Cisplatin forms intra- and inter-strand DNA crosslinks, blocking replication and transcription (Zhang et al., 2025, https://doi.org/10.1038/s44319-025-00590-7).
• p53-dependent apoptotic pathways are activated following DNA damage by cisplatin, leading to caspase-3 and -9 activation (Zhang et al., 2025, DOI).
• Cisplatin elevates ROS, resulting in oxidative stress and lipid peroxidation in cancer cells (Zhang et al., 2025, DOI).
• In vivo, intravenous administration of 5 mg/kg cisplatin on days 0 and 7 significantly inhibits tumor growth in xenograft models (APExBIO product dossier, APExBIO).
• Cisplatin is insoluble in water and ethanol but soluble at ≥12.5 mg/mL in DMF; DMSO inactivates its cytotoxic activity (APExBIO).

Applications, Limits & Misconceptions

Cisplatin is a mainstay in cancer research for investigating DNA damage, apoptosis induction, and mechanisms of chemotherapy resistance. It is extensively used in both in vitro and in vivo models, including studies of ovarian, head and neck, and lung cancers. The compound facilitates apoptosis assays, cytotoxicity profiling, and exploration of p53 and caspase signaling pathways. Recent studies also leverage cisplatin to dissect the interplay between DNA damage and m6A methylation in RNA processing (Zhang et al., 2025).

This article builds upon the practical workflows outlined in Cisplatin (SKU A8321): Scenario-Based Guidance by providing molecular benchmarks for apoptosis and resistance studies. It updates the perspective in Cisplatin: Gold Standard DNA Crosslinking Agent for Cancer Research by integrating recent findings about ROS and ERK signaling. For a focused analysis of cisplatin-induced resistance, see Cisplatin in Cancer Research: Unraveling Resistance and Apoptosis; this article uniquely clarifies optimal solvent strategies and benchmarks for in vivo dosing.

Common Pitfalls or Misconceptions

• Solubility Errors: Cisplatin is ineffective if dissolved in DMSO; use DMF to preserve cytotoxicity (APExBIO).
• Storage Stability: Solutions are unstable; always prepare fresh aliquots before use and store powder in the dark at room temperature.
• Overgeneralization: Cisplatin is not universally effective against all cancer cell lines; resistance mechanisms may limit efficacy.
• Misinterpreting Apoptosis Assays: Caspase-3 and -9 activation is required for cisplatin-induced apoptosis, but alternative death pathways may complicate readouts.
• Non-selective Cytotoxicity: Cisplatin induces broad cytotoxic effects and is not a selective agent for one pathway or cell type.

Workflow Integration & Parameters

Cisplatin is supplied as a powder and should be stored at room temperature in the dark to maintain stability. For cell-based assays, dissolve at ≥12.5 mg/mL in DMF using gentle warming and ultrasonic treatment. Solutions must be freshly prepared; avoid DMSO as a solvent due to irreversible inactivation. In vivo studies commonly use intravenous dosing at 5 mg/kg on day 0 and day 7 in xenograft models, achieving significant tumor growth inhibition. Apoptosis assays should measure caspase-3/-9 activity, p53 stabilization, and ROS generation for mechanistic insights. For chemotherapy resistance studies, incremental exposure protocols and combination regimens are recommended (Cisplatin in Cancer Research: Integrating DNA Crosslinking, Apoptosis Assays, and EGFR Resistance).

Conclusion & Outlook

Cisplatin remains a cornerstone chemotherapeutic compound for dissecting DNA damage response, apoptosis, and resistance mechanisms in cancer research. Molecular benchmarks—including DNA crosslinking, caspase pathway activation, and ROS generation—ensure precise experimental design. Proper storage and solvent selection are critical for reproducibility and activity. As new findings link DNA damage to RNA methylation and genome stability, cisplatin will continue to serve as an essential tool for mechanistic and translational studies. For detailed product specifications, refer to the Cisplatin A8321 kit from APExBIO.